These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3595699)

  • 1. Pharmacokinetics of ketanserin in patients with essential hypertension.
    Persson B; Pettersson A; Hedner T
    Eur J Clin Pharmacol; 1987; 32(3):259-65. PubMed ID: 3595699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.
    Heykants J; Van Peer A; Woestenborghs R; Gould S; Mills J
    Eur J Clin Pharmacol; 1986; 31(3):343-50. PubMed ID: 3792432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
    Hedner T; Pettersson A; Persson B
    J Hypertens Suppl; 1986 Apr; 4(1):S91-3. PubMed ID: 2939221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketanserin pharmacokinetics in patients with renal failure.
    Barendregt JN; Van Peer A; Van Der Hoeven JG; Van Oene JC; Tjandra YI
    Br J Clin Pharmacol; 1990 Jun; 29(6):715-23. PubMed ID: 2378791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ketanserin in man.
    Reimann IW; Okonkwo PO; Klotz U
    Eur J Clin Pharmacol; 1983; 25(1):73-6. PubMed ID: 6617728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.
    Williams FM; Leeser JE; Rawlins MD
    Br J Clin Pharmacol; 1986 Sep; 22(3):301-8. PubMed ID: 3768242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the acute sublingual administration of ketanserin in hypertensive patients.
    Aliberti G; D'Erasmo E; Oddo CM; Vecci E
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):697-9. PubMed ID: 1888692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and pharmacokinetics of ketanserin in elderly subjects.
    Kurowski M
    Eur J Clin Pharmacol; 1985; 28(4):411-7. PubMed ID: 3161741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ketanserin in patients with cirrhosis.
    Lebrec D; Hadengue A; Gaudin C; Levron JC; Fraitag B; Berthelot P; Benhamou JP
    Clin Pharmacokinet; 1990 Aug; 19(2):160-6. PubMed ID: 2379381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
    Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
    Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of ketanserin.
    Persson B; Heykants J; Hedner T
    Clin Pharmacokinet; 1991 Apr; 20(4):263-79. PubMed ID: 2036747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjects.
    Waller PC; Tucker GT; Ramsay LE
    Eur J Clin Pharmacol; 1987; 33(4):423-6. PubMed ID: 3443148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol.
    Van Peer A; Woestenborghs R; Embrechts L; Heykants J
    Eur J Clin Pharmacol; 1986; 31(3):339-42. PubMed ID: 3792431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?
    Gould SE; Silas JH; Hosie J
    Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():89-92. PubMed ID: 2285655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
    Levinson PD; Zimlichman R; Goldstein DS; Keiser HR
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):384-9. PubMed ID: 2465437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemodynamic and humoral effects of 2 different doses of ketanserin in aged patients with hypertension].
    Rizzoni D; Castellano M; Beschi M; Agabiti-Rosei E
    Ann Ital Med Int; 1990; 5(4 Pt 2):489-96. PubMed ID: 2102136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.
    Trenk D; Mosler A; Kirch W; Meinertz T; Jähnchen E
    J Cardiovasc Pharmacol; 1983; 5(6):1034-9. PubMed ID: 6196551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients.
    Kleinbloesem CH; van Brummelen P; Faber H; Breimer DD
    J Cardiovasc Pharmacol; 1987 Feb; 9(2):202-8. PubMed ID: 2435999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of chronic ketanserin therapy on blood pressure and certain humoral and metabolic factors in patients with mild to moderate primary essential hypertension].
    Knypl K; Wocial B; Berent H; Kuçzyńska K; Wasowska T; Brym E; Czerniewska E; Wacławek-Maczkowska J; Januszewicz W
    Pol Arch Med Wewn; 1993 Aug; 90(2):95-104. PubMed ID: 8247951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Felodipine pharmacokinetics and plasma concentration vs effect relationships.
    Blychert E
    Blood Press Suppl; 1992; 2():1-30. PubMed ID: 1343111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.